Daniel T Myran, Jennifer Xiao, Nicholas Fabiano, Michael Pugliese, Tyler S Kaster, Joshua D Rosenblat, M Ishrat Husain, Jess G Fiedorowicz, Stanley Wong, Peter Tanuseputro, Marco Solmi
{"title":"与普通人群相比,接受致幻剂急性住院治疗的患者的死亡风险。","authors":"Daniel T Myran, Jennifer Xiao, Nicholas Fabiano, Michael Pugliese, Tyler S Kaster, Joshua D Rosenblat, M Ishrat Husain, Jess G Fiedorowicz, Stanley Wong, Peter Tanuseputro, Marco Solmi","doi":"10.1503/cmaj.241191","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Although clinical trials involving psychedelic-assisted psychotherapy have not observed short-term increases in the risk of death, limited data exist on mortality associated with hallucinogen use outside of controlled trial settings. We sought to determine whether people with an emergency department visit or hospital admission involving hallucinogen use were at increased risk of all-cause death compared with the general population and with people with acute care presentations involving other substances.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study using linked health administrative data on all people aged 15 years and older living in Ontario, Canada, from 2006 to 2022. We compared overall and cause-specific mortality between members of the general population and people with incident acute care (an emergency department visit or hospital admission) involving hallucinogens and other substances.</p><p><strong>Results: </strong>We included 11 415 713 people; 7953 (0.07%) had incident acute care involving hallucinogens. In a matched analysis with 77 101 people with a median follow-up of 7 (interquartile range 3-11) years, acute care involving hallucinogens was associated with a 2.6-fold (hazard ratio [HR] 2.57, 95% confidence interval [CI] 2.09-3.15) increased all-cause mortality within 5 years (<i>n</i> = 482, absolute risk 6.1%) relative to the general population (<i>n</i> = 460, absolute risk 0.6%). Analyses excluding people with comorbid mental or substance use disorders showed similar elevations in mortality risk for acute care involving hallucinogens relative to the general population (HR 3.25, 95% CI 2.27-4.63). People with acute care involving hallucinogens were at a significantly elevated risk of death by unintentional drug poisoning (HR 2.03, 95% CI 1.02-4.05), suicide (HR 5.23, 95% CI 1.38-19.74), respiratory disease (HR 2.46, 95% CI 1.18-5.11), and cancer (HR 2.88, 95% CI 1.61-5.14) relative to the general population.</p><p><strong>Interpretation: </strong>Requiring hospital-based care for hallucinogen use was associated with increases in risk of death relative to the general population, particularly from suicide. These findings should be considered in clinical and policy decision-making, given the increasing use of hallucinogens and associated problematic use.</p>","PeriodicalId":9609,"journal":{"name":"Canadian Medical Association journal","volume":"197 8","pages":"E204-E213"},"PeriodicalIF":9.4000,"publicationDate":"2025-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11879370/pdf/","citationCount":"0","resultStr":"{\"title\":\"Mortality risk among people receiving acute hospital care for hallucinogen use compared with the general population.\",\"authors\":\"Daniel T Myran, Jennifer Xiao, Nicholas Fabiano, Michael Pugliese, Tyler S Kaster, Joshua D Rosenblat, M Ishrat Husain, Jess G Fiedorowicz, Stanley Wong, Peter Tanuseputro, Marco Solmi\",\"doi\":\"10.1503/cmaj.241191\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Although clinical trials involving psychedelic-assisted psychotherapy have not observed short-term increases in the risk of death, limited data exist on mortality associated with hallucinogen use outside of controlled trial settings. We sought to determine whether people with an emergency department visit or hospital admission involving hallucinogen use were at increased risk of all-cause death compared with the general population and with people with acute care presentations involving other substances.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study using linked health administrative data on all people aged 15 years and older living in Ontario, Canada, from 2006 to 2022. We compared overall and cause-specific mortality between members of the general population and people with incident acute care (an emergency department visit or hospital admission) involving hallucinogens and other substances.</p><p><strong>Results: </strong>We included 11 415 713 people; 7953 (0.07%) had incident acute care involving hallucinogens. In a matched analysis with 77 101 people with a median follow-up of 7 (interquartile range 3-11) years, acute care involving hallucinogens was associated with a 2.6-fold (hazard ratio [HR] 2.57, 95% confidence interval [CI] 2.09-3.15) increased all-cause mortality within 5 years (<i>n</i> = 482, absolute risk 6.1%) relative to the general population (<i>n</i> = 460, absolute risk 0.6%). Analyses excluding people with comorbid mental or substance use disorders showed similar elevations in mortality risk for acute care involving hallucinogens relative to the general population (HR 3.25, 95% CI 2.27-4.63). People with acute care involving hallucinogens were at a significantly elevated risk of death by unintentional drug poisoning (HR 2.03, 95% CI 1.02-4.05), suicide (HR 5.23, 95% CI 1.38-19.74), respiratory disease (HR 2.46, 95% CI 1.18-5.11), and cancer (HR 2.88, 95% CI 1.61-5.14) relative to the general population.</p><p><strong>Interpretation: </strong>Requiring hospital-based care for hallucinogen use was associated with increases in risk of death relative to the general population, particularly from suicide. These findings should be considered in clinical and policy decision-making, given the increasing use of hallucinogens and associated problematic use.</p>\",\"PeriodicalId\":9609,\"journal\":{\"name\":\"Canadian Medical Association journal\",\"volume\":\"197 8\",\"pages\":\"E204-E213\"},\"PeriodicalIF\":9.4000,\"publicationDate\":\"2025-03-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11879370/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Canadian Medical Association journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1503/cmaj.241191\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Medical Association journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1503/cmaj.241191","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
摘要
背景:虽然涉及致幻剂辅助心理治疗的临床试验未观察到死亡风险的短期增加,但在对照试验环境之外,关于致幻剂使用与死亡率相关的数据有限。我们试图确定与使用致幻剂的人相比,急诊科就诊或住院的人与使用其他药物的人相比,是否有更高的全因死亡风险。方法:我们对2006年至2022年居住在加拿大安大略省的所有15岁及以上的人进行了回顾性队列研究,使用相关的健康管理数据。我们比较了涉及致幻剂和其他物质的普通人群和突发急性护理(急诊科就诊或住院)人群的总体死亡率和原因特异性死亡率。结果:纳入11 415 713人;7953例(0.07%)发生过涉及致幻剂的急性护理。在一项匹配分析中,77 101人的中位随访时间为7年(四分位间距为3-11年),涉及致幻剂的急性护理与5年内全因死亡率(n = 482,绝对风险6.1%)相对于普通人群(n = 460,绝对风险0.6%)增加2.6倍(风险比[HR] 2.57, 95%置信区间[CI] 2.09-3.15)相关。排除精神或物质使用障碍共病者的分析显示,与一般人群相比,涉及致幻剂的急性护理的死亡风险类似升高(HR 3.25, 95% CI 2.27-4.63)。与一般人群相比,接受致幻剂急性护理的患者因意外药物中毒(HR 2.03, 95% CI 1.02-4.05)、自杀(HR 5.23, 95% CI 1.38-19.74)、呼吸系统疾病(HR 2.46, 95% CI 1.18-5.11)和癌症(HR 2.88, 95% CI 1.61-5.14)死亡的风险显著升高。解释:与一般人群相比,使用致幻剂需要住院治疗与死亡风险增加有关,尤其是自杀。鉴于致幻剂使用的增加和相关的问题使用,这些发现应在临床和政策决策中加以考虑。
Mortality risk among people receiving acute hospital care for hallucinogen use compared with the general population.
Background: Although clinical trials involving psychedelic-assisted psychotherapy have not observed short-term increases in the risk of death, limited data exist on mortality associated with hallucinogen use outside of controlled trial settings. We sought to determine whether people with an emergency department visit or hospital admission involving hallucinogen use were at increased risk of all-cause death compared with the general population and with people with acute care presentations involving other substances.
Methods: We conducted a retrospective cohort study using linked health administrative data on all people aged 15 years and older living in Ontario, Canada, from 2006 to 2022. We compared overall and cause-specific mortality between members of the general population and people with incident acute care (an emergency department visit or hospital admission) involving hallucinogens and other substances.
Results: We included 11 415 713 people; 7953 (0.07%) had incident acute care involving hallucinogens. In a matched analysis with 77 101 people with a median follow-up of 7 (interquartile range 3-11) years, acute care involving hallucinogens was associated with a 2.6-fold (hazard ratio [HR] 2.57, 95% confidence interval [CI] 2.09-3.15) increased all-cause mortality within 5 years (n = 482, absolute risk 6.1%) relative to the general population (n = 460, absolute risk 0.6%). Analyses excluding people with comorbid mental or substance use disorders showed similar elevations in mortality risk for acute care involving hallucinogens relative to the general population (HR 3.25, 95% CI 2.27-4.63). People with acute care involving hallucinogens were at a significantly elevated risk of death by unintentional drug poisoning (HR 2.03, 95% CI 1.02-4.05), suicide (HR 5.23, 95% CI 1.38-19.74), respiratory disease (HR 2.46, 95% CI 1.18-5.11), and cancer (HR 2.88, 95% CI 1.61-5.14) relative to the general population.
Interpretation: Requiring hospital-based care for hallucinogen use was associated with increases in risk of death relative to the general population, particularly from suicide. These findings should be considered in clinical and policy decision-making, given the increasing use of hallucinogens and associated problematic use.
期刊介绍:
CMAJ (Canadian Medical Association Journal) is a peer-reviewed general medical journal renowned for publishing original research, commentaries, analyses, reviews, clinical practice updates, and editorials. Led by Editor-in-Chief Dr. Kirsten Patrick, it has a significant impact on healthcare in Canada and globally, with a 2022 impact factor of 17.4.
Its mission is to promote knowledge vital for the health of Canadians and the global community, guided by values of service, evidence, and integrity. The journal's vision emphasizes the importance of the best evidence, practice, and health outcomes.
CMAJ covers a broad range of topics, focusing on contributing to the evidence base, influencing clinical practice, and raising awareness of pressing health issues among policymakers and the public. Since 2020, with the appointment of a Lead of Patient Involvement, CMAJ is committed to integrating patients into its governance and operations, encouraging their content submissions.